{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:30:56Z","timestamp":1792229456945,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emerging information suggests that gastrointestinal and systemic pathology states may affect expression and function of membrane transporters in the gastrointestinal tract. Altered status of the transporters could affect drug as well as endogenous compounds handling with subsequent clinical consequences. It seems that in some pathologies, e.g., liver or kidney failure, changes in the intestinal transporter function provide compensatory functions, eliminating substrates excreted by dysfunctional organs. A literature search was conducted on Ovid and Pubmed databases to select relevant in vitro, animal and human studies that have reported expression, protein abundance and function of intestinal drug transporters. The accumulated data suggest that gastrointestinal pathology (inflammatory bowel disease, celiac disease, cholestasis) as well as systemic pathologies (kidney failure, liver failure, hyperthyroidism, hyperparathyroidism, obesity, diabetes mellitus, systemic inflammation and Alzheimer disease) may affect drug transporter expression and function in the gastrointestinal tract. The altered status of drug transporters may provide compensatory activity in handling endogenous compounds, affect local drug actions in the gastrointestinal tract as well as impact drug bioavailability.<\/jats:p><jats:p><jats:bold>Graphic abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s43440-020-00139-6","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T04:53:32Z","timestamp":1595825612000},"page":"1173-1194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Intestinal drug transporters in pathological states: an overview"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-7168","authenticated-orcid":false,"given":"Marek","family":"Drozdzik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Czekawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Oswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Drozdzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"139_CR1","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/cpt.1112","volume":"104","author":"MJ Zamek-Gliszczynski","year":"2018","unstructured":"Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, et al. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. Clin Pharm Ther. 2018;104:890\u20139.","journal-title":"Clin Pharm Ther"},{"key":"139_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1515\/hsz-2016-0259","volume":"398","author":"J M\u00fcller","year":"2017","unstructured":"M\u00fcller J, Keiser M, Drozdzik M, Oswald S. Expression, regulation and function of intestinal drug transporters: an update. Biol Chem. 2017;398:175\u201392.","journal-title":"Biol Chem"},{"key":"139_CR3","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.2174\/0929867323666161024154457","volume":"23","author":"M Drozdzik","year":"2016","unstructured":"Drozdzik M, Oswald S. Expression and regulation of drug transporters and metabolizing enzymes in the human gastrointestinal tract. Curr Med Chem. 2016;23:4468\u201389.","journal-title":"Curr Med Chem"},{"key":"139_CR4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.addr.2012.09.042","volume":"65","author":"M Estudante","year":"2013","unstructured":"Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: an overview. Adv Drug Deliv Rev. 2013;65:1340\u201356.","journal-title":"Adv Drug Deliv Rev"},{"key":"139_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1124\/pr.113.007518","volume":"65","author":"J K\u00f6nig","year":"2013","unstructured":"K\u00f6nig J, M\u00fcller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65:944\u201366.","journal-title":"Pharmacol Rev"},{"key":"139_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1515\/bc.2011.017","volume":"392","author":"W Kramer","year":"2011","unstructured":"Kramer W. Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery. Biol Chem. 2011;392:77\u201394.","journal-title":"Biol Chem"},{"key":"139_CR7","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1021\/mp500330y","volume":"11","author":"M Drozdzik","year":"2014","unstructured":"Drozdzik M, Gr\u00f6er C, Penski J, Lapczuk J, Ostrowski M, Lai Y, Prasad B, et al. Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. Mol Pharm. 2014;11:3547\u201355.","journal-title":"Mol Pharm"},{"key":"139_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cpt.1301","volume":"105","author":"M Drozdzik","year":"2019","unstructured":"Drozdzik M, Busch D, Lapczuk J, M\u00fcller J, Ostrowski M, Kurzawski M, et al. Protein abundance of clinically relevant drug transporters in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2019;105:1204\u201312.","journal-title":"Clin Pharmacol Ther"},{"key":"139_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s11095-005-2588-5","volume":"22","author":"W Weitschies","year":"2005","unstructured":"Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, et al. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res. 2005;22:728\u201335.","journal-title":"Pharm Res"},{"key":"139_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","volume":"17","author":"Q Mao","year":"2015","unstructured":"Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport: an update. AAPS J. 2015;17:65\u201382.","journal-title":"AAPS J"},{"key":"139_CR11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1124\/jpet.108.146647","volume":"328","author":"T Watanabe","year":"2009","unstructured":"Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328:652\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"139_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.mam.2012.11.003","volume":"34","author":"DE Smith","year":"2013","unstructured":"Smith DE, Cl\u00e9men\u00e7on B, Hediger MA. Proton-coupled oligopeptide transporter family SLC15: physiological pharmacological and pathological implications. Mol Aspects Med. 2013;34:323\u201336.","journal-title":"Mol Aspects Med"},{"key":"139_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/095632029200300305","volume":"3","author":"L Beauchamp","year":"1992","unstructured":"Beauchamp L, Orr G, de Miranda P, Burnette T, Krenitsky TA. Amino acid ester prodrugs of aciclovir. Antviral Chem Chemother. 1992;3:157\u201364.","journal-title":"Antviral Chem Chemother"},{"key":"139_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41581-019-0111-1","volume":"15","author":"SK Nigam","year":"2019","unstructured":"Nigam SK, Bush KT. Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling. Nat Rev Nephrol. 2019;15:301\u201316.","journal-title":"Nat Rev Nephrol"},{"key":"139_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0014-2999(00)00699-3","volume":"406","author":"ZH Huang","year":"2000","unstructured":"Huang ZH, Murakami T, Okochi A, Yumoto R, Nagai J, Takano M. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol. 2000;406:453\u201360.","journal-title":"Eur J Pharmacol"},{"key":"139_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1124\/jpet.106.112631","volume":"320","author":"J Naud","year":"2007","unstructured":"Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther. 2007;320:978\u201385.","journal-title":"J Pharmacol Exp Ther"},{"key":"139_CR17","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1681\/ASN.2009010082","volume":"20","author":"TD Nolin","year":"2009","unstructured":"Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009;20:2269\u201376.","journal-title":"J Am Soc Nephrol"},{"key":"139_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1248\/bpb.27.384","volume":"27","author":"N Shibata","year":"2004","unstructured":"Shibata N, Inoue Y, Fukumoto K, Nishimura A, Fukushima K, Yoshikawa Y, et al. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure. Biol Pharm Bull. 2004;27:384\u201391.","journal-title":"Biol Pharm Bull"},{"key":"139_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","volume":"109","author":"H Sun","year":"2006","unstructured":"Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1\u201311.","journal-title":"Pharmacol Ther"},{"key":"139_CR20","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/ndt\/16.8.1607","volume":"16","author":"C Veau","year":"2001","unstructured":"Veau C, Leroy C, Banide H, Auchere D, Tardivel S, Farinotti R, et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant. 2001;16:1607\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"139_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1211\/0022357021771931","volume":"54","author":"H Okabe","year":"2002","unstructured":"Okabe H, Yano I, Hashimoto Y, Saito H, Inui K. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. J Pharm Pharmacol. 2002;54:65\u201370.","journal-title":"J Pharm Pharmacol"},{"key":"139_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10157-013-0806-8","volume":"18","author":"H Yano","year":"2014","unstructured":"Yano H, Tamura Y, Kobayashi K, Tanemoto M, Uchida S. Uric acid transporter ABCG2 is increased in the intestine of the 5\/6 nephrectomy rat model of chronic kidney disease. Clin Exp Nephrol. 2014;18:50\u20135.","journal-title":"Clin Exp Nephrol"},{"key":"139_CR23","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.","journal-title":"Nat Commun"},{"key":"139_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ckj\/sfw010","volume":"9","author":"V Bhatnagar","year":"2016","unstructured":"Bhatnagar V, Richard EL, Wu W, Nievergelt CM, Lipkowitz MS, Jeff J, et al. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. Clin Kidney J. 2016;9:444\u201353.","journal-title":"Clin Kidney J"},{"key":"139_CR25","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1073\/pnas.0901249106","volume":"106","author":"OM Woodward","year":"2009","unstructured":"Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA. 2009;106:10338\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"139_CR26","doi-asserted-by":"publisher","first-page":"F130","DOI":"10.1152\/ajprenal.00114.2013","volume":"306","author":"Z Gai","year":"2014","unstructured":"Gai Z, Chu L, Hiller C, Arsenijevic D, Penno CA, Montani JP, et al. Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. Am J Physiol Renal Physiol. 2014;306:F130\u2013137.","journal-title":"Am J Physiol Renal Physiol"},{"key":"139_CR27","doi-asserted-by":"publisher","first-page":"G664","DOI":"10.1152\/ajpgi.00270.2004","volume":"288","author":"Y Shimizu","year":"2005","unstructured":"Shimizu Y, Masuda S, Nishihara K, Ji L, Okuda M, Inui K. Increased protein level of PEPT1 intestinal H+-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5\/6 nephrectomized rats. Am J Physiol Gastrointest Liver Physiol. 2005;288:G664\u2013670.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"139_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1211\/0022357011776036","volume":"53","author":"ZH Huang","year":"2001","unstructured":"Huang ZH, Murakami T, Okochi A, Yumoyo R, Nagai J, Takano M. Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure. J Pharm Pharmacol. 2001;53:873\u201381.","journal-title":"J Pharm Pharmacol"},{"key":"139_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1023\/A:1023485519485","volume":"20","author":"R Yumoto","year":"2003","unstructured":"Yumoto R, Murakami T, Takano M. Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine. Pharm Res. 2003;20:765\u201371.","journal-title":"Pharm Res"},{"key":"139_CR30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1038\/aps.2017.54","volume":"38","author":"F Wang","year":"2017","unstructured":"Wang F, Miao MX, Sun BB, Wang ZJ, Tang XG, Chen Y, et al. Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp. Acta Pharmacol Sin. 2017;38:1554\u2013655.","journal-title":"Acta Pharmacol Sin"},{"key":"139_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejphar.2006.06.079","volume":"546","author":"T Yokooji","year":"2006","unstructured":"Yokooji T, Murakami T, Yumoto R, Nagai J, Takano M. Function of multidrug resistance-associated protein 2 in acute hepatic failure rats. Eur J Pharmacol. 2006;546:152\u201360.","journal-title":"Eur J Pharmacol"},{"key":"139_CR32","first-page":"102","volume":"57","author":"T Murakami","year":"2002","unstructured":"Murakami T, Yumoto R, Nagai J, Takano M. Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states. Pharmazie. 2002;57:102\u20137.","journal-title":"Pharmazie"},{"key":"139_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1124\/dmd.110.034512","volume":"38","author":"A Mennone","year":"2010","unstructured":"Mennone A, Soroka CJ, Harry KM, Boyer JL. Role of breast cancer resistance protein in the adaptive response to cholestasis. Drug Metab Dispos. 2010;38:1673\u20138.","journal-title":"Drug Metab Dispos"},{"key":"139_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11095-007-9495-x","volume":"25","author":"N Nishio","year":"2008","unstructured":"Nishio N, Katsura T, Inui K. Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells. Pharm Res. 2008;25:1037\u201342.","journal-title":"Pharm Res"},{"key":"139_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1124\/dmd.32.8.779","volume":"32","author":"T Mitin","year":"2004","unstructured":"Mitin T, von Moltke LL, Court MH, Greenblatt DJ. Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. Drug Metab Dispos. 2004;32:779\u201382.","journal-title":"Drug Metab Dispos"},{"key":"139_CR36","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1124\/dmd.105.004770","volume":"33","author":"N Nishio","year":"2005","unstructured":"Nishio N, Katsura T, Ashida K, Okuda M, Inui K. Modulation of P-glycoprotein expression in hyperthyroid rat tissues. Drug Metab Dispos. 2005;33:1584\u20137.","journal-title":"Drug Metab Dispos"},{"key":"139_CR37","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2133\/dmpk.20.324","volume":"20","author":"M Jin","year":"2005","unstructured":"Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K. Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine. Drug Metab Pharmacokinet. 2005;20:324\u201330.","journal-title":"Drug Metab Pharmacokinet"},{"key":"139_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1067\/mcp.2002.126706","volume":"72","author":"W Siegmund","year":"2002","unstructured":"Siegmund W, Altmannsberger S, Paneitz A, Hecker U, Zschiesche M, Franke G, et al. Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther. 2002;72:256\u201364.","journal-title":"Clin Pharmacol Ther"},{"key":"139_CR39","doi-asserted-by":"publisher","first-page":"G617","DOI":"10.1152\/ajpgi.00344.2001","volume":"282","author":"K Ashida","year":"2002","unstructured":"Ashida K, Katsura T, Motohashi H, Saito H, Inui K. Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2002;282:G617\u2013623.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"139_CR40","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1023\/B:PHAM.0000029285.45101.ee","volume":"21","author":"K Ashida","year":"2004","unstructured":"Ashida K, Katsura T, Saito H, Inui K. Decreased activity and expression of intestinal oligopeptide transporter PEPT1 in rats with hyperthyroidism in vivo. Pharm Res. 2004;21:969\u201375.","journal-title":"Pharm Res"},{"key":"139_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.kint.2016.09.041","volume":"91","author":"R Sugimoto","year":"2017","unstructured":"Sugimoto R, Watanabe H, Ikegami K, Enoki Y, Imafuku T, Sakaguchi Y, et al. Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 2017;91:658\u201370.","journal-title":"Kidney Int"},{"key":"139_CR42","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1007\/s10620-013-2636-7","volume":"58","author":"N Verma","year":"2013","unstructured":"Verma N, Ahuja V, Paul J. Profiling of ABC transporters during active ulcerative colitis and in vitro effect of inflammatory modulators. Dig Dis Sci. 2013;58:2282\u201392.","journal-title":"Dig Dis Sci"},{"key":"139_CR43","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.lfs.2011.08.019","volume":"89","author":"A Nawa","year":"2011","unstructured":"Nawa A, Fujita-Hamabe W, Tokuyama S. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Life Sci. 2011;89:834\u20138.","journal-title":"Life Sci"},{"key":"139_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.lfs.2010.01.009","volume":"86","author":"A Nawa","year":"2010","unstructured":"Nawa A, Fujita Hamabe W, Tokuyama S. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci. 2010;86:402\u20139.","journal-title":"Life Sci"},{"key":"139_CR45","doi-asserted-by":"crossref","unstructured":"Gravel S, Panzini B, Belanger F, Turgeon J, Michaud V. A Pilot Study towards the impact of type 2 diabetes on the expression and activities of drug metabolizing enzymes and transporters in human duodenum. Int J Mol Sci. 2019;20. pii: E3257.","DOI":"10.3390\/ijms20133257"},{"key":"139_CR46","doi-asserted-by":"publisher","first-page":"C821","DOI":"10.1152\/ajpcell.1999.276.4.C821","volume":"276","author":"M Thamotharan","year":"1999","unstructured":"Thamotharan M, Bawani SZ, Zhou X, Adibi SA. Hormonal regulation of oligopeptide transporter Pept-1 in a human intestinal cell line. Am J Physiol Cell Physiol. 1999;276:C821\u2013C826826.","journal-title":"Am J Physiol Cell Physiol"},{"key":"139_CR47","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/bdd.689","volume":"30","author":"N Sugioka","year":"2009","unstructured":"Sugioka N, Haraya K, Fukushima K, Ito Y, Takada K. Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats. Biopharm Drug Dispos. 2009;30:532\u201341.","journal-title":"Biopharm Drug Dispos"},{"key":"139_CR48","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1021\/acs.molpharmaceut.5b00656","volume":"13","author":"C Lloret-Linares","year":"2016","unstructured":"Lloret-Linares C, Miyauchi E, Luo H, Labat L, Bouillot JL, Poitou C, et al. Oral morphine pharmacokinetic in obesity: the role of P-glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 jejunal contents and obesity-associated biomarkers. Mol Pharm. 2016;13:766\u201373.","journal-title":"Mol Pharm"},{"key":"139_CR49","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1021\/acs.molpharmaceut.6b00085","volume":"13","author":"E Miyauchi","year":"2016","unstructured":"Miyauchi E, Tachikawa M, Decl\u00e8ves X, Uchida Y, Bouillot JL, Poitou C, et al. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. Mol Pharm. 2016;13:2631\u201340.","journal-title":"Mol Pharm"},{"key":"139_CR50","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1172\/JCI13219","volume":"108","author":"M Buyse","year":"2001","unstructured":"Buyse M, Berlioz F, Guilmeau S, Tsocas A, Voisin T, P\u00e9ranzi G, et al. PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin in the small intestine. J Clin Invest. 2001;108:1483\u201394.","journal-title":"J Clin Invest"},{"key":"139_CR51","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/jps.20072","volume":"93","author":"AM Belliard","year":"2004","unstructured":"Belliard AM, Lacour B, Farinotti R, Leroy C. Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J Pharm Sci. 2004;93:1524\u201336.","journal-title":"J Pharm Sci"},{"key":"139_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.18433\/J30300","volume":"15","author":"S Hanafy","year":"2012","unstructured":"Hanafy S, El-Kadi AO, Jamali F. Effect of inflammation on molecular targets and drug transporters. J Pharm Pharm Sci. 2012;15:361\u201375.","journal-title":"J Pharm Pharm Sci"},{"key":"139_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1124\/dmd.32.1.20","volume":"32","author":"J Kalitsky-Szirtes","year":"2004","unstructured":"Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004;32:20\u20137.","journal-title":"Drug Metab Dispos"},{"key":"139_CR54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ibd.20030","volume":"13","author":"G Englund","year":"2007","unstructured":"Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, R\u00f6nnblom A. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm Bowel Dis. 2007;13:291\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"139_CR55","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.xphs.2018.09.024","volume":"108","author":"P Erdmann","year":"2019","unstructured":"Erdmann P, Bruckmueller H, Martin P, Busch D, Haenisch S, M\u00fcller J, et al. Dysregulation of mucosal membrane transporters and drug-metabolizing enzymes in ulcerative colitis. J Pharm Sci. 2019;108:1035\u201346.","journal-title":"J Pharm Sci"},{"key":"139_CR56","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1124\/dmd.114.058065","volume":"42","author":"J Jahnel","year":"2014","unstructured":"Jahnel J, Fickert P, Hauer AC, H\u00f6genauer C, Avian A, Trauner M. Inflammatory bowel disease alters intestinal bile acid transporter expression. Drug Metab Dispos. 2014;42:1423\u201331.","journal-title":"Drug Metab Dispos"},{"key":"139_CR57","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.prp.2013.12.010","volume":"210","author":"D Plewka","year":"2014","unstructured":"Plewka D, Plewka A, Szczepanik T, Morek M, Bogunia E, Wittek P, et al. Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions. Pathol Res Pract. 2014;210:242\u20139.","journal-title":"Pathol Res Pract"},{"key":"139_CR58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000179361","volume":"78","author":"H Gutmann","year":"2008","unstructured":"Gutmann H, Hruz P, Zimmermann C, Straumann A, Terracciano L, Hammann F, et al. Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion. 2008;78:154\u201362.","journal-title":"Digestion"},{"key":"139_CR59","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2217\/pgs.09.128","volume":"10","author":"M Ufer","year":"2009","unstructured":"Ufer M, H\u00e4sler R, Jacobs G, Haenisch S, L\u00e4chelt S, Faltraco F, et al. Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics. 2009;10:1941\u201353.","journal-title":"Pharmacogenomics"},{"key":"139_CR60","first-page":"367","volume":"61","author":"YJ Zhang","year":"2014","unstructured":"Zhang YJ, Wang P, Zhang Y, Zheng YF, Jin JJ, Wang JL. Effects of 5-amino salicylic acid on the expression of multidrug resistance gene in ulcerative colitis. Hepatogastroenterology. 2014;61:367\u201372.","journal-title":"Hepatogastroenterology"},{"key":"139_CR61","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/00498250110060969","volume":"31","author":"A Ayrton","year":"2001","unstructured":"Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001;31:469\u201397.","journal-title":"Xenobiotica"},{"key":"139_CR62","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.4049\/jimmunol.161.10.5733","volume":"161","author":"CM Panwala","year":"1998","unstructured":"Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733\u201344.","journal-title":"J Immunol"},{"key":"139_CR63","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s11033-014-3127-4","volume":"41","author":"J Wang","year":"2014","unstructured":"Wang J, Guo X, Yu S, Zhang J, Song J, Ji M, et al. MDR1 C3435T polymorphism and inflammatory bowel disease risk: a meta-analysis. Mol Biol Rep. 2014;41:2679\u201385.","journal-title":"Mol Biol Rep"},{"key":"139_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/mp050113v","volume":"3","author":"H Zaher","year":"2006","unstructured":"Zaher H, Khan AA, Palandra J, et al. Breast cancer resistance protein (Bcrp\/Abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm. 2006;3:55\u201361.","journal-title":"Mol Pharm"},{"key":"139_CR65","doi-asserted-by":"publisher","first-page":"15649","DOI":"10.1073\/pnas.202607599","volume":"99","author":"JW Jonker","year":"2002","unstructured":"Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA. 2002;99:15649\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"139_CR66","first-page":"6447","volume":"63","author":"AE van Herwaarden","year":"2003","unstructured":"van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (Bcrp1\/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 2003;63:6447\u2013522.","journal-title":"Cancer Res"},{"key":"139_CR67","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1124\/dmd.109.027367","volume":"37","author":"KA Wojtal","year":"2009","unstructured":"Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, et al. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab Dispos. 2009;37:1871\u20137.","journal-title":"Drug Metab Dispos"},{"key":"139_CR68","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.crohns.2011.08.003","volume":"6","author":"M Girardin","year":"2012","unstructured":"Girardin M, Dionne S, Goyette P, Rioux J, Bitton A, Elimrani I, et al. Expression and functional analysis of intestinal organic cation\/L-carnitine transporter (OCTN) in Crohn\u2019s disease. J Crohns Colitis. 2012;6:189\u201397.","journal-title":"J Crohns Colitis"},{"key":"139_CR69","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1203\/PDR.0b013e3181e5bc96","volume":"68","author":"A Vannay","year":"2010","unstructured":"Vannay A, Sziksz E, Pr\u00f3kai A, Veres G, Moln\u00e1r K, Szak\u00e1l DN, et al. Increased expression of hypoxia-inducible factor 1alpha in coeliac disease. Pediatr Res. 2010;68:118\u201322.","journal-title":"Pediatr Res"},{"key":"139_CR70","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1021\/acs.molpharmaceut.8b00500","volume":"15","author":"Y Pan","year":"2018","unstructured":"Pan Y, Omori K, Ali I, Tachikawa M, Terasaki T, Brouwer KLR, et al. Altered expression of small intestinal drug transporters and hepatic metabolic enzymes in a mouse model of familial Alzheimer\u2019s disease. Mol Pharm. 2018;15:4073\u201383.","journal-title":"Mol Pharm"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00139-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00139-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00139-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T21:54:27Z","timestamp":1696456467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00139-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00139-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}